Your browser doesn't support javascript.
loading
Stability of plasminogen activator inhibitor-1: role of tyrosine221.
Sui, G C; Wiman, B.
Afiliação
  • Sui GC; Department of Clinical Chemistry and Blood Coagulation, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden.
FEBS Lett ; 423(3): 319-23, 1998 Feb 27.
Article em En | MEDLINE | ID: mdl-9515731
Using site-directed mutagenesis, changes of Tyr221 in plasminogen activator inhibitor-1 (PAI-1) have provided mutants with normal activity, but with increased stability. At physiological conditions, the transition of the PAI-1 mutants Tyr221His and Tyr221Ser to the latent form was significantly prolonged (half-lives 14.8 and 4.1 h, respectively) as compared to wild-type PAI-1 (2.0 h). Their half-lives, especially for the Tyr221Ser mutant, were even more prolonged in the presence of vitronectin (23.8 and 53.7 h, respectively). While wild-type PAI-1 was more stable at lower pH, the PAI-1 mutants Tyr221His and Tyr221Ser had stability optima at about pH 6.5, but displayed shorter half-lives at pH 5.5.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Tirosina / Estabilidade Enzimática / Inibidor 1 de Ativador de Plasminogênio Limite: Humans Idioma: En Revista: FEBS Lett Ano de publicação: 1998 Tipo de documento: Article País de afiliação: Suécia
Buscar no Google
Base de dados: MEDLINE Assunto principal: Tirosina / Estabilidade Enzimática / Inibidor 1 de Ativador de Plasminogênio Limite: Humans Idioma: En Revista: FEBS Lett Ano de publicação: 1998 Tipo de documento: Article País de afiliação: Suécia